Results 31 to 40 of about 35,838 (264)

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer [PDF]

ESMO Open, 2022
The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) targets human epidermal growth factor receptor 2 (HER2) and has been evaluated in patients with HER2-positive unresectable/metastatic breast cancer in the phase II DESTINY-Breast01 trial (NCT03248492; DS8201-A-U201) and the randomized phase III DESTINY-Breast03 trial (NCT03529110; DS8201-A-U302)
Rugo H. S., Bianchini G., Cortes J., Henning J. -W., Untch M.   +4 more
openaire   +4 more sources

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.

New England Journal of Medicine, 2020
BACKGROUND Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
K. Shitara, Y. Bang, S. Iwasa, N. Sugimoto, M. Ryu, D. Sakai, H. Chung, H. Kawakami, H. Yabusaki, Jeeyun Lee, K. Saito, Y. Kawaguchi, T. Kamio, A. Kojima, M. Sugihara, K. Yamaguchi   +15 more
semanticscholar   +1 more source

Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases

Current Problems in Cancer: Case Reports, 2020
Trastuzumab deruxtecan has been shown to have responses in heavily pretreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.
Nicole Higashiyama, Julie Nangia, Maryam Nemati Shafaee, Nan Chen, Binu Liz Michael, Mothaffar Rimawi, Valentina Hoyos   +6 more
doaj   +1 more source

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines

Therapeutic Advances in Medical Oncology, 2022
Background: Evidence to date supports continued human epidermal growth factor receptor 2 (HER2) suppression beyond progression on HER2-directed therapy for advanced HER2-positive breast cancer.
Christine Simmons, Daniel Rayson, Anil Abraham Joy, Jan-Willem Henning, Julie Lemieux, Heather McArthur, Paul B. Card, Rebecca Dent, Christine Brezden-Masley   +8 more
doaj   +1 more source

Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era [PDF]

Journal of Immunotherapy and Precision Oncology, 2023
HER2-targeted therapy with the HER2 monoclonal antibody trastuzumab has achieved impressive outcomes in the first-line settings of patients with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma overexpressing HER2. However, considering
Maluki Radford, Hassan Abushukair, Stijn Hentzen, Ludimila Cavalcante, Anwaar Saeed   +4 more
doaj   +1 more source

Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers

Cancer Control, 2022
Epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression and/or amplification confers a more aggressive clinical behavior but also represents a therapeutic opportunity for targeted therapies in breast cancer (BC).
Alessandro Rizzo MD, Antonio Cusmai MD, Raffaella Massafra PhD, Samantha Bove PhD, Maria Colomba Comes PhD, Annarita Fanizzi PhD, Gennaro Gadaleta-Caldarola MD, Donato Oreste MD, Alfredo Zito MD, Francesco Giotta MD, Vito Lorusso MD, Gennaro Palmiotti MD   +11 more
doaj   +1 more source

[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.

PLoS ONE, 2019
[Fam-] trastuzumab deruxtecan (DS-8201a) is a HER2 (ERBB2)-targeting antibody-drug conjugate, composed of a HER2-targeting antibody and a topoisomerase I inhibitor, exatecan derivative, that has antitumor effects in preclinical xenograft models and ...
Tomomi Nakayama Iwata, Kiyoshi Sugihara, Teiji Wada, Toshinori Agatsuma   +3 more
doaj   +1 more source

Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles

Current Oncology, 2023
Antibody drug conjugates (ADCs) have emerged as a highly effective treatment strategy across breast cancer (BC) subtypes, including human epidermal growth factor receptor 2-positive (HER2+), hormone-receptor positive (ER/PR+), and triple-negative breast ...
Mary Anne Fenton, Paolo Tarantino, Stephanie L. Graff   +2 more
doaj   +1 more source

The Rapidly Changing Treatment Landscape of Systemic Therapy for HER-2 Positive Metastatic Breast Cancer

healthbook TIMES. Oncology Hematology, 2021
Human epidermal growth factor receptor 2 (HER-2) overexpressed breast cancer has traditionally been considered as an aggressive disease with high risk of systemic and brain metastases and poor prognosis.
Larissa Russo-Vorms, Christoforos Astaras, José Sandoval, Maxime Borgeaud, Alexandre Bodmer   +4 more
doaj   +1 more source

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

Nature Communications, 2023
DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prior regimens ...
T. Yoshino, M. Di Bartolomeo, K. Raghav, T. Masuishi, F. Loupakis, H. Kawakami, K. Yamaguchi, T. Nishina, Z. Wainberg, E. Élez, Javier Rodríguez, M. Fakih, F. Ciardiello, K. Saxena, Kojiro Kobayashi, E. Bako, Y. Okuda, G. Meinhardt, A. Grothey, S. Siena   +19 more
semanticscholar   +1 more source